Clinical trial Recruiting at 1 site Observational Ages 18 and up

Exploring neoadjuvant therapy for lung cancer

Official title: Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study

Run by Shanghai Pulmonary Hospital, Shanghai, China · NCT06216782 · Data updated 2026-11-12

This study is testing how well different treatments before surgery, like chemotherapy and immunotherapy, can help people with lung cancer and what factors might affect their success.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorShanghai Pulmonary Hospital, Shanghai, China
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedDecember 16, 2023
Main results expectedDecember 30, 2033
Study endsDecember 30, 2033
Registry record updatedJanuary 22, 2024
Trial IDNCT06216782 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with a confirmed diagnosis of non-small cell lung cancer or small cell lung cancer who have received neoadjuvant therapy.

Probably not a fit

Patients currently enrolled in other clinical trials or those who refuse follow-up may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of various neoadjuvant therapies, including chemotherapy, immunotherapy, and targeted therapy, in patients with lung cancer. It focuses on understanding how different patient characteristics influence treatment outcomes and the long-term survival rates associated with these therapies. By analyzing real-world clinical data, the study seeks to identify the strengths and weaknesses of different neoadjuvant regimens in improving surgical resection rates and overall therapeutic effects.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies that enhance survival rates for lung cancer patients.

How similar studies have gone: Previous studies have shown promising results with neoadjuvant therapies in lung cancer, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age greater than or equal to 18 years;
2. Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer;
3. Received neoadjuvant therapy after diagnosis;
4. Written informed consent.

Exclusion Criteria:

1. Patients enrolled in other clinical trials;
2. Patients refused enrollment in this study;
3. Patients refused follow-up.

Where it's running

  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.